8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Feb 26, 2026·SEC
BioLife Solutions, Inc.(BLFS)Earnings, Financials & Key Ratios
BLFS•NASDAQ
$27.93
Price updated Jul 7, 2026
AboutBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.Show more
- Revenue$96M+17.0%
- EBITDA-$9M-711.9%
- Net Income-$12M+39.9%
- EPS (Diluted)-0.25+43.2%
- Gross Margin64.56%-1.1%
- EBITDA Margin-9.74%-623.2%
- Operating Margin-12.61%-45.5%
- Net Margin-12.61%+48.6%
- ROE-3.37%+42.8%
BLFS Price & Volume
BioLife Solutions, Inc. (BLFS) stock price & volume — 10-year historical chart
Loading chart...
Strategic Pivot Faces Persistent Operational Margin Volatility
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Mixed
Cash Flow:Mixed
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- BioLife Solutions is currently navigating a complex transition toward a leaner, consumables-focused business model, evidenced by a significant reduction in total debt from $41.0M in 2024Q1 to $14.9M in 2026Q1.
- While the company maintains resilient gross margins consistently above 60%, the reliance on volatile biotech funding cycles and high stock-based compensation—often exceeding $5M per quarter—creates structural uncertainty regarding long-term profitability.
- Investors should monitor the company's ability to convert its $208.6M goodwill base into sustainable operating cash flow, as current earnings quality remains obscured by erratic OCF/NI ratios.
Verdict Logic
while the company has successfully deleveraged its balance sheet to a 0.04 debt-to-equity ratio, the persistent reliance on $4.8M in quarterly stock-based compensation and inconsistent cash conversion suggests that operational stability is not yet fully established.
BLFS Growth Metrics
BioLife Solutions, Inc. (BLFS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years31.03%
5 Years14.88%
3 Years8.07%
TTM40.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM8.46%
Return on Capital
10 Years-7.98%
5 Years-4.43%
3 Years-3.74%
Last Year-3.24%
BLFS Recent Earnings
BioLife Solutions, Inc. (BLFS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.04+300.0%
$0.01
Rev
$28M+7.2%
$26M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.04+300.0%
$0.02
Rev
$25M+2.9%
$24M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.04+1900.0%
$0.00
Rev
$28M+9.3%
$26M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.33-888.5%
$0.03
Rev
$25M-1.0%
$26M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.04vs $0.01+300.0% | $28Mvs $26M+7.2% |
| Q1 2026 | Feb 26, 2026 | $0.04vs $0.02+300.0% | $25Mvs $24M+2.9% |
| Q4 2025 | Nov 6, 2025 | $0.04vs $0.00+1900.0% | $28Mvs $26M+9.3% |
| Q3 2025 | Aug 7, 2025 | $0.33vs $0.03-888.5% | $25Mvs $26M-1.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BioLife Solutions, Inc. (BLFS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.93 | $1.36B | -111.72 | 16.97% | -12.61% | -3.37% | — | |
| $7.58 | $1.98B | -24.45 | 18.96% | -73.63% | -36.79% | — | |
| $25.37 | $1.17B | -20.80 | 3.55% | -29.86% | -10.69% | — | |
| $15.06 | $755.98M | 10.76 | -24.47% | 42.17% | 16.16% | — | |
| $139.83 | $7.89B | 162.59 | 16.36% | 6.73% | 2.46% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — |
Compare BLFS vs Peers
BioLife Solutions, Inc. (BLFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BLFS SEC Filings & Documents
BioLife Solutions, Inc. (BLFS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BLFS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BLFS Frequently Asked Questions
BioLife Solutions, Inc. (BLFS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is BioLife Solutions, Inc.'s revenue?
BioLife Solutions, Inc. (BLFS) reported $99.8M in revenue for fiscal year 2025. This represents a 634% increase from $13.6M in 1995.
How fast is BioLife Solutions, Inc. growing?
BioLife Solutions, Inc. (BLFS) grew revenue by 17.0% over the past year. This is strong growth.
Is BLFS profitable?
BioLife Solutions, Inc. (BLFS) reported a net loss of $10.5M for fiscal year 2025.
Dividend & Returns
What is BLFS's return on equity?
BioLife Solutions, Inc. (BLFS) has a return on equity (ROE) of -3.4%. Negative ROE indicates the company is unprofitable.
What is BioLife Solutions, Inc.'s free cash flow?
BioLife Solutions, Inc. (BLFS) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.